Similar articles

• Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.

  Lipton A, Zheng M, Seaman J. Lipton A, et al. Cancer. 2003 Sep 1;98(5):962-9. doi: 10.1002/cncr.11571. Cancer. 2003. PMID: 12942563 Clinical Trial.
• Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.

  Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Lipton A, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6397S-403S. doi: 10.1158/1078-0432.CCR-040030. Clin Cancer Res. 2004. PMID: 15448038 Review.
• Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.

  Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S. Kohno N, et al. J Clin Oncol. 2005 May 20;23(15):3314-21. doi: 10.1200/JCO.2005.05.116. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738536 Clinical Trial.
• [Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].

  Arima S, Shiroki R, Mori S, Maruyama T, Sasaki H, Kusaka M, Miyakawa S, Hayakawa K, Hoshinaga K. Arima S, et al. Nihon Hinyokika Gakkai Zasshi. 2008 Jul;99(5):660-5. doi: 10.5980/jpnjurol1989.99.660. Nihon Hinyokika Gakkai Zasshi. 2008. PMID: 18697474 Japanese.
• Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.

  Saad F, Lipton A. Saad F, et al. BJU Int. 2005 Nov;96(7):964-9. doi: 10.1111/j.1464-410X.2005.05740.x. BJU Int. 2005. PMID: 16225510 Review.